Table 2.
Case-control study: preadmission statin use and risk of hospitalization for pneumonia in Denmark (1997-2009)
| Statin use | Pneumonia cases (n = 70,914) |
Population controls (n = 709,140) |
Crudea OR (95% CI) |
Adjustedb OR (95% CI) |
|---|---|---|---|---|
| Never | 61,783 (87.1%) | 630,515 (88.9%) | 1.00 (reference) | 1.00 (reference) |
| Former (>125 days before admission) | 1,908 (2.7%) | 14,102 (2.0%) | 1.42 (1.35-1.50) | 0.97 (0.91-1.02) |
| Current (≤125 days before admission) | 7,223 (10.2%) | 64,523 (9.1%) | 1.17 (1.14-1.21) | 0.80 (0.77-0.83) |
| Current (≤125 days before admission), supplementary adjusted model for 2001-2009 | 6,883 (13.0%) | 61,450 (11.6%) | 1.18 (1.15-1.21) | 0.77 (0.74-0.80) |
aMatched for age, sex, urbanization of place of residence, and hospitalization/index date. bAdjusted for marital status, calendar period, living with small children, any recent surgical procedure, 20 different comorbidities, alcoholism-related conditions, and 18 different preadmission medications (Table 1). The supplementary model for 2001-2009 includes 53,160 pneumonia cases and 531,600 controls and is also adjusted for receipt of current year's influenza vaccine, dementia, social medicine-related consultations, application for reimbursement for chronic or terminal illness, conversational therapy, and general practitioner preventive consultations and services. CI, confidence interval; OR, odds ratio.